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Abstract
Background—The translation of research evidence into practice is facilitated by clinical trials
such as those sponsored by the National Cancer Institute’s Community Clinical Oncology
Program (CCOP) that help disseminate cancer care innovations to community-based physicians
and provider organizations. However, CCOP participation involves unsubsidized costs and
organizational challenges that raise concerns about sustained provider participation in clinical
trials.
Objectives—This study was designed to improve our understanding of why providers participate
in the CCOP in order to inform the decision-making process of administrators, clinicians,
organizations, and policy-makers considering CCOP participation.
Research Methods—We conducted a multi-site qualitative study of five provider organizations
engaged with the CCOP. We interviewed 41 administrative and clinician key informants, asking
about what motivated CCOP participation, and what benefits they associated with involvement.
We deductively and inductively analyzed verbatim interview transcripts, and explored themes that
emerged.
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Results—Interviewees expressed both “altruistic” and “self-interested” motives for CCOP
participation. Altruistic reasons included a desire to increase access to clinical trials and feeling an
obligation to patients. Self-interested reasons included the desire to enhance reputation, and a need
to integrate disparate cancer care activities. Perceived benefits largely matched expressed motives
for CCOP participation, and included internal and external benefits to the organization, and quality
of care benefits for both patients and participating physicians.
Conclusion—The motives and benefits providers attributed to CCOP participation are consistent
with translational research goals, offering evidence that participation can contribute value to
providers by expanding access to innovative medical care for patients in need.
Keywords
clinical trials; cancer; community-based participatory research; health services research;
qualitative research; organizational decision making; community networks; research support as
topic
INTRODUCTION
With advances in clinical research rapidly changing the provision of medical care, the need
to efficiently and effectively translate research evidence into practice is increasingly
important [1–7]. Clinical trials serve a vital role in this evidence translation process as new
treatments are offered to eligible patients by practicing providers willing to pursue clinical
trials research and report their findings based on the experiences of their patients with the
protocols under study.
In the area of cancer, the National Cancer Institute’s (NCI)1 Community Clinical Oncology
Program (CCOP), a provider-based research network (PBRN), helps to disseminate and
implement innovations in cancer care by supporting a research infrastructure that links
academic institutions and investigators to community-based physicians and medical groups
[5,8]. The CCOP structure thus helps to promote advances in cancer treatments among
community providers by expanding access to clinical trials and disseminating research
findings about new interventions and technologies that might not be typically available [5,9–
10].
Yet similar to the challenges of other clinical trials research, participation in the CCOP can
involve costs to both hospitals and physicians that are not fully subsidized by the NCI [5].
Previous studies have identified several barriers to community physician participation in
clinical trials research [5,11–15], and many challenges to sustaining such participation over
the long term [5,15–17]. Less well understood is what motivates hospitals and community
physicians to participate in clinical trials such as the CCOP, and what benefits they report
from their participation.
We designed a qualitative study to learn more about the reasons organizations and
physicians participate in the CCOP, including both what motivates their initial participation
decisions, and their perceptions of the benefits they obtain that contribute to their decisions
to continue to participate in the CCOP. We were especially interested in learning about these
factors from the perspectives of the organizational and physician providers involved in the
CCOP, including those making decisions about CCOP participation. Improving our
understanding of these motives and benefits can help inform the decision-making processes
of administrators, clinicians, organizations, and policymakers considering the opportunities
1Abbreviations Used: National Cancer Institute (NCI); Community Clinical Oncology Program (CCOP); Provider-Based Research
Network (PBRN)
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and potential impacts of CCOP participation in the context of challenging economic
conditions.
METHODS
We used a multiple case-study design [18] in a qualitative study [19] to investigate the
motives behind physician and organizational participation in the NCI’s CCOP. Below we
further describe our site selection, study sample, data collection, and analytic methods. The
Institutional Review Boards of The Ohio State University and the University of North
Carolina, Chapel Hill, approved the study protocol.
Study Setting
The NCI’s CCOP was established in 1983 to extend the reach of Phase III clinical trials
focused on cancer prevention, control and treatment to community practice settings. There
are presently 47 CCOP organizations throughout the United States, representing 340
hospitals and 2,900 community-based physicians (e.g., oncologists, surgeons, OB/GYNs)
[20]. We use the term “CCOP provider organizations” to refer to the hospitals and physician
practices affiliated with the CCOP organizations.
Individual CCOP organizations receive peer-reviewed research grant funding through the
NCI, with grant awards dependent on research productivity and patient recruitment to
clinical trials. However, CCOP grants are typically insufficient to cover the full costs
associated with maintaining a research infrastructure [5], thus CCOP provider organizations
commonly need to subsidize CCOP participation.
Study Sample
Given our study design, we purposively selected participating sites in order to ensure
variability across CCOP organizations with respect to the dimensions of size, structure,
location, and length of operations as a CCOP (i.e., CCOP maturity). Our study sample
included five sites: two mature CCOP organizations, in operation for more than 10 years;
two that had been part of the CCOP for fewer than 10 years; and one that had applied to the
NCI’s CCOP but had not yet been awarded a CCOP grant. At the conclusion of interviews
across these fives sites we found that we had reached saturation with respect to respondents’
answers to our questions, thus giving us confidence that our sample size was sufficient.
Data Collection
We conducted a total of 41 telephonic key informant interviews across the five study sites
between August 2008 and April 2010. At each study site we identified a key contact person
(e.g., the CCOP principal investigator or CCOP administrator). We then asked that person to
identify additional key informants associated with the CCOP provider organization (both
administrators and clinicians), and community-based practicing physicians who were
involved in CCOP-related clinical trials research. Organizational key informants (n=20)
included those administrators and staff members who were involved in CCOP provider
organization operations and included directors, managers, and finance personnel. Clinician
key informants (n=18) included both physicians (n=11) and nurses (n=7), and included
community-based physicians associated with all sites’ CCOP provider organizations (see
Table 1). Informed consent was obtained from all key informants.
Interviewers used two versions of a standardized guide (i.e., one for organizational
informants and one for physician informants) to conduct the interviews. The interview
guides were comprised of semi-structured questions and follow-up question probes,
including direct questions about motives for and benefits of CCOP participation. The two
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interview guides asked similar questions of both respondent groups, but question wording
was tailored to the professional role of the interviewee (i.e., physician versus non-
physician).
Questions about motives directed interviewees to consider the reasons why their
organization or they had decided to participate in the CCOP (e.g., “What was your
organization’s primary motivation for becoming [part of] a CCOP organization?”).
Questions about benefits asked interviewees to consider the benefits of CCOP participation,
based on their experience with the CCOP (e.g., “How has your organization benefited from
participation in the CCOP?”). Interviews lasted from 30–60 minutes. The majority of
interviews were conducted by one study investigator, with a second investigator available on
the call to assist. All interviews were recorded, transcribed verbatim, and then verified and
corrected by study investigators.
Analyses
We used a combination of deductive and inductive methods to analyze our interview data.
First, using a grounded theory approach [20–21], we read transcripts and discussed
preliminary findings as our study progressed. Then, after completion of all the interviews,
we formed an analysis team that included the lead qualitative investigator and two research
assistants to code all the transcripts.
For the deductive portion of our study, we developed a preliminary coding book including
codes based on responses to the direct questions that had been asked of key informants.
Coders then used this coding book to code the same three transcripts and come to agreement
about codes and code definitions. As the study and coding processes progressed, coders met
periodically in order to ensure consistency among coders and agreement about the
emergence of themes within the data.
The inductive portion of our study involved iteratively analyzing interview transcripts to
identify themes [22] related to motives and benefits of participation. Coders would identify
these emergent themes, enabling us to then explore new themes in subsequent interviews as
the case studies proceeded. We used the Atlas.ti qualitative data analysis software program
to facilitate coding and analyses [23].
RESULTS
Motives for Participation in the CCOP
When asked why they participated in the CCOP, both organizational and physician
interviewees provided two main types of reasons that we categorized thematically as
“altruistic,” or externally-focused reasons, and “self-interested,” or internally-focused
reasons. We next discuss these reasons by theme, and provide additional representative
quotations in Table 2.
“Altruistic” Reasons for CCOP Participation—Interviewees listed multiple reasons
for participating in the CCOP, many of which were related to concern about others outside
their organization(s). These “altruistic” reasons included providing access to clinical trials
for community residents and participating in research because it was what “should be done.”
For instance, interviewees across all five CCOP organizations noted CCOP participation
was an important way to provide access to clinical trials for their patients or potential
patients. Informants appeared convinced that offering clinical trials as treatment options was
part of providing the best care possible, thus making trials available was viewed as clinically
important. As one administrator explained, “I think the primary focus was to provide clinical
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trials here in [location] for our local cancer patients and not to make our patients travel so far
for the trials.” Another interviewee, summarizing what he/she believed to be the collective
sentiment of that organization’s participating physicians explained, “I really believe, from an
altruistic standpoint, that the oncologists truly believe in the benefit of research and having
that as an option available to patients.”
As many interviewees’ further explained, they felt a type of professional or even “moral”
obligation to participate based on organizational or clinical goals. As described by one
administrator, “I think it was jointly held values and the principle that as a leader in
healthcare in the state, it was our obligation to work with physicians to bring state-of-the-art
treatment to local populations across the state as much as possible.” A physician similarly
reflected how, “We looked at it and we said, this is an absolute. We can’t take care of cancer
patients without having access to clinical trials.”
“Self-Interested” Reasons for CCOP Participation—Both organizational and
physician interviewees also listed reasons for CCOP participation that were related to their
organization’s or their own interests. For example, the opportunity for CCOP participation
to improve both the organizations’ and the physicians’ reputations was noted as an important
motivator across interviewees. One administrator explained that CCOP participation was
sought, “to advance the reputation of the institution.” A physician summarized this
motivator nicely for both groups explaining, “The reason we do this is that you want to
make a name for yourself as an institution that can do this on its own.”
Another type of internally-focused reason involved the desire to integrate and organize
cancer services. As one administrator explained, “The main reason why we wanted to
become a CCOP was to try and create a mechanism to really have one research program and
one primary source of access to NCI-funded clinical trials.” Similarly, a physician described,
“We had a lot of duplication with some of our programs and we had pockets where we were
doing some stuff, but we weren’t doing others. So it really became part of helping us
standardize and put together a complete picture around cancer.” For the larger CCOP
organizations, the motivation to integrate cancer activities was particularly strong.
Perceived Benefits of CCOP Participation
When asked about the benefits that CCOP participation provided, interviewees described
multiple types of benefits. We categorized these benefits thematically into three groups: 1)
internal organizational benefits; 2) external organizational benefits; and 3) quality of care
benefits. Below we describe these themes in greater detail, with additional verbatim
comments supporting these categorizations presented in Table 3.
Internal Benefits to Provider Organizations—Internal benefits to the provider
organizations largely involved the issues of physician and patient recruitment and retention.
For instance, interviewees across the five sites consistently noted that an important benefit
of CCOP participation was an enhanced ability to recruit and retain physicians. As one
administrator described a recent physician recruitment effort: “One of the specific questions
that they [the physician candidates] had for us was what research we do here.” Physicians
similarly noted this benefit. One reflected, “We also have hired breast surgeons and so forth
who’ve mentioned that part of their decision was that we have the clinical research
available. That was an unanticipated but significant benefit of participating in the CCOP
grant.”
The ability to attract and retain patients was also commonly mentioned as a benefit of CCOP
participation. As one administrator explained, “[W]hen our patients go [elsewhere], [the
other hospital] will also send them back if we have a trial open here… So I’m certain that
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we’re keeping more patients here because of our research participation.” Both organizational
and physician interviewees additionally noted that CCOP participation could involve
spillover benefits to other areas of the hospital; as one organizational interviewee
commented, “[It] helps them to increase the amount of patients who are having services here
at the hospital.”
External Organizational Benefits—Interviewees’ descriptions of external benefits to
the provider organizations largely involved the perception that CCOP participation enhanced
their reputation in the community, thereby improving their organization’s “status” and
providing them with leverage for clinical trials. A majority of informants reported that they
perceived that an improved reputation in their communities was indeed a benefit of CCOP
participation, and this was consistent with their previous explanations that the potential for a
better community reputation motivated CCOP participation. As one administrator noted, “A
very good reputation, that comes along with it. Kind of like a status thing [from the
perspective of] other institutions.” Physicians were also quick to list this benefit, making
comments about how they are now “on the map for cancer care,” and that, “it makes the
practice more prestigious.”
This enhanced reputation through CCOP participation also reportedly benefited providers by
giving both organizations and individual physicians leverage to expand their research
activities, including involvement in pharmaceutical industry-sponsored clinical trials. This
was reportedly a benefit because industry-sponsored trials were typically well-reimbursed,
thus additional trial participation could contribute to efforts to support and sustain the cancer
research infrastructures of these provider organizations. One administrator explained, “being
a CCOP, we have to already have established certain certifications and things like that so
that’s going to make us more appealing and desirable. Because we’ve already done a lot of
the groundwork and footwork and have processes in place.”
Quality of Care Benefits—In addition, quality of care benefits were consistently noted
across sites and interviewees. These benefits included interviewees’ perceptions that CCOP
participation benefited physicians by providing opportunities for continuing education, and
the notion that this continuing education thereby enabled provision of higher-quality care.
Specifically, helping physicians stay current with advances in cancer therapies was
mentioned by both interviewee groups as an important benefit of CCOP participation. As
one administrator mentioned, “So I think it’s just a good way to get everybody well
educated in terms of what is going on in the rest of the country in terms of clinical trials. I
think it’s also a good way for them to stay in tune with the literature. Follow it.” The
specific opportunity the CCOP provided for physicians to network with other physicians to
keep abreast of developments in cancer treatments was also mentioned in this context. One
physician commented, “You know, it’s a chance to network. When you go to these meetings
[CCOP meetings] and you talk to other physicians from other institutions, you also bring
back something you don’t practice. I think it’s a chance to be more involved with cutting-
edge care and bring it back to your institution.”
In addition, interviewees’ reportedly believed that CCOP participation involved the
opportunity to provide better care quality explicitly because of access to clinical research
trials through the CCOP. As one administrator noted, “I just think that there is more
awareness as to what’s state-of-the-art and potentially what will be state-of-the-art in a year
or two.” Physicians were similarly positive about their abilities to offer better care to
patients. One physician explained, “It drives the quality of the oncology group, then drives
the quality of the other specialists because they demand the same kind of attention to detail
and attention to conferences and review of patients and transparent care patterns, high use of
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the protocol, etc. So it creates an academic environment that helps us sustain the whole
thing.”
DISCUSSION
This study was designed to improve our understanding of why providers were motivated to
participate in a CCOP, and to learn about the benefits they perceived to be associated with
that participation in order to help the broad audience of administrators, organizations,
clinicians and policymakers who may be considering the opportunities and potential impacts
of CCOP participation. We found that the interviewees we spoke with about their CCOP
involvement shared similar perspectives about the motives and benefits of CCOP
participation, with the motives often linked to their perceptions about the benefits of
participation. For example, many interviewees noted that they participated in the CCOP
because they hoped to improve their reputations as either organizations or providers, and
they later noted that improved reputations were benefits they associated with CCOP
participation.
Overall, organizational and physician interviewees reported both “altruistic” (external) and
“self-interested” (internal) motives for CCOP participation. These motives are consistent
with the results of prior studies showing that CCOPs have a positive global impact on
research, despite findings that certain types of cancer research may only indirectly impact
the participating organization, its patients and its providers [24]. Similarly, our findings
about the perceived benefits of participation are aligned with the results of recent research
that have shown that CCOP participation is associated with increases in accruals to clinical
trials [e.g., 25–26], thus providing evidence that CCOP participation can help provider
organizations expand and support their cancer research efforts.
Yet given the current economic climate and financial pressures placed upon provider
organizations, the sustainability of CCOP organizations as important players in clinical trials
research networks is not guaranteed [4–5,12–15]. Our study suggests that there are
numerous organizational and societal benefits of CCOP participation (e.g., better quality of
care), and these were noted across informant groups. Further, our interviewees’ reflections
about participation benefits are consistent with the goals of the NCI’s CCOP, and research
that has demonstrated the value of CCOPs as a means of effectively translating research into
practice [25–28]. The next step, though, must involve additional effort to measure a business
case for CCOP participation, particularly in the face of an increasing need for organizations
to justify continued financial support of activities such as CCOP studies that are an
invaluable component of translational and dissemination research, but may not contribute
obviously or directly to the organization’s bottom line [29–33].
Interestingly, while interviewees’ reported many intangible motives for CCOP participation
(e.g., being the “right thing to do,” improving their reputations), the benefits they reported
associating with participation could conceivably be quantified. For instance, reported
improvements in physician and patient recruitment and retention were not explicitly
expected, but were noted across all sites, and could be measured if organizations wanted to
track the impact of CCOP participation. Similarly, unexpected quality of care benefits could
be monitored with respect to patient outcomes, physician compliance with guidelines and
protocols, and so forth. More directly, provider organizations could track their progress with
respect to obtaining research contracts and grants with pharmaceutical companies and other
agencies, thereby providing tangible evidence of the benefits of CCOP participation.
From a policy and research perspective, the NCI can help sustain the CCOP by using the
results of this study to explicitly strengthen motives for CCOP participation and enhance
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both participation benefits and awareness of these benefits. While the challenges of
documenting these benefits and quantifying a business case remain, the results of our study
highlight the importance of both tangible and non-financial benefits that can and should be
taken into account in any assessment of the value of clinical trials, and particularly CCOP,
participation.
Limitations
Predictably, our study has a number of limitations. First, while our site selection approach
was comprehensive, our research design limited our study to five purposively selected
CCOP organizations. It is possible that a different set of CCOP organizations might have
allowed us to explore different motives and benefits of CCOP participation. In addition, our
approach to key informant selection could have biased our findings in favor of CCOP
participation, as all informants had knowledge of the CCOP and its activities. Nonetheless,
our multiple interviews of both organizational and physician representatives across the five
sites give us confidence that our findings do resonate with interviewees across these varied
CCOP organizations, and that our findings are consistent across informant types.
Our study is also limited by the time frame during which it was conducted. Recognizing that
NCI funding and CCOP participation are, in practice, dynamic processes, we were limited
by our ability to interview informants at a single point in time. Finally, our findings may be
limited in their applicability to cancer research and cancer clinical trials. It is conceivable
that the motives and benefits we find associated with CCOP participation may be less
compelling in other fields where state-of-the art clinical trials are less common.
Future studies can help extend this research by using designs that are both longitudinal and
quantitative, and use opportunities to blend qualitative considerations with measures of
quality of care and outcomes associated with trial participation.
Conclusion
Given the importance of disseminating and implementing innovations in medical care, our
research shows that the motives providers report for participating in CCOPs are consistent
with translational research goals. Further, our findings support the value of CCOPs in
helping both organizations and physicians in their efforts to expand access to clinical trials
research to local communities and patients for whom such access might not otherwise be
available. A better understanding of these motives and benefits can help both provider
organizations and physician providers justify and sustain their commitment to clinical trials
and the CCOP over time, thus maintaining critical access to innovative care for patients in
need.
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Table 1
CCOP Case Study Site Characteristics
CCOP Site
CCOP Maturity (Years in
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Table 2
Motives for CCOP Participation
Organizational Perspectives Physician Perspectives
“Altruistic,” Externally-Focused Motives
“… primary motivation was to present clinical trials
for patients so that it’s nearer to their home versus
going, you know, outside of their area to obtain
clinical trials.”
“We have the only central city medical center in
[location]. So part of it I think was a responsibility to
go after this.”
“I think that we’re a non-profit community hospital
and we’re here to serve the community in which we
reside so all of our decisions are based on how to
best serve our community.”
“So our primary motivation was that as a healthcare
system, clinical research was a high priority across
the United States. It should be a high priority for the
quality of care that we wanted to provide.”
“[W]e definitely believe that participating in clinical
trials is the right way to go in terms of pushing the
organization forward”
“the CCOP basically allows us to put
clinical trials into the community where
the majority of patients are being
treated.”
“getting these studies to the rural areas
that would not typically be able to have
them without the CCOP being here.”
“So our involvement was purely
academic and helping human kind. … I
mean we never thought of … oncology
as a business. So we had very pure
motives.”
“Probably the main motivation …
everything we do is a patient-centered
approach: our vision is centered on the
patient.”
“When we started initially it was for
academia.”
“Self- Interested,” Internally- Focused
Motives
“We wanted to see our own program as opposed to
being an affiliate.”
“…enhance [the organization’s] position and its
ability to offer services….”
“So I think the motivation of the greater
[organization] is to bring us all together, you know,
somewhat simplify the mechanism that’s happening
in many areas throughout the oncology practice of
[location] and, again, have perhaps a little better
control over what’s occurring.”
“So if we had a CCOP then if you open up a study, it
opens up system-wide. That would have really cut
down on the amount of paperwork and the amount of
time it takes to open up one study at each site. And
that was actually one of the important things.”
“the CCOP was a way to distinguish us
as a major provider of oncology care in
this area.”
“…it would be a prestigious thing to
have. It will be recognized as something
—a feather in your cap to be a CCOP.”
“And you know when you have a lot of
private practice physicians, oncologists,
who then come together, it would be
nice to have that platform for them to
come together on. …The CCOP would
have really allowed for us to
reorganize.”
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Table 3
Perceived Benefits of CCOP Participation
Organizational Perspectives Physician Perspectives
Internal Organizational Benefits
“[I]t has helped us in the recruitment of
physicians… The new doctors coming out of
school want to go to a place that offers clinical
trials and that they can participate in research.”
“to bring in better physicians, to engage physicians
at a higher level”
“I know there are patients that know [this
organization] because of the CCOP.”
“You know, we retain patients here. They kind of
walk them through every step of the way
throughout their care.”
“Attracting and retaining high-quality physicians.
…I think having the CCOP has made that easy.”
“And the unexpected benefit as far as getting
better doctors will also get you more patients.”
“So we benefit by having that additional business
that you know drives and feeds everybody’s work
around here. So you come here with an oncology
problem and you end up having a neurologic
problem. … so everybody benefits.”
External Organizational Benefits
“And I think it also enhanced our reputation among
patients and residents of [this area] and around to
know that they can rely on us and they don’t have
to go [to other places].”
“it elevates the community’s impression of the
institution.” “it has definitely helped us bring in
pharmaceutical contracts and things like that.”
“I think it’s also increased our reputation as being
an organization that is committed to research, that
is committed to being cutting-edge.”
“I certainly think other funders would view that as
a positive if they were making a decision about
placing their funds within a particular organization
to know that an organization had achieved the
status of being a CCOP.”
“There is, you know, prestige, and the fact that
your practice is very well-respected and having
the ability to claim that you are a part of the
National Cancer Research Institute network has a
lot of value.”
“I think that the CCOP would probably make us
more attractive because it sort of lends an air of
organization. … otherwise you wouldn’t have
been awarded the CCOP grant.”
“we are large enough as a CCOP that now that
NCI, you know, they almost can’t do some of the
big studies without engaging us.”
“You know, if you develop a reputation as
somebody that is a guardian of the data and you
take that seriously, that reputation’s going to carry
over to those trials. And I think pharmaceutical
companies are smart enough to know there are
certain places they’re going to stay away from and
there are certain places they’re going try to go to
to open trials up.”
Quality of Care Benefits “Whether it’s new guidelines, new clinical
pathways, new options for treatment. Things like
that to keep it in the forefront and push things that
it’s designed to push our outcomes to a higher
level.”
“The quality of care is higher because of their
involvement within research.”
“Those are things that are standard now, but they
were done earlier here because we were
participating in trials.”
“It’s allowed us to be able to offer to our patients a
much broader spectrum of treatment options.”
“I think when you are actively involved in
research protocols it really keeps you actively
involved in what is going on and changes and the
trends.”
“So I guess that makes me feel current…and it
makes me feel that I’m contributing to an effort so
I won’t have to tell the patients the same old tired
stuff that I’ve been telling them for the last 25
years.”
“And what it’s helped me do is to give patients
cutting-edge treatments that wouldn’t be available
otherwise.”
“Getting new drugs to patients, changing the way
that we practice oncology. Those are the two
major benefits.”
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